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Abstract 
Deletion and duplication of 16p11.2 (BP4-BP5) have been associated with increased 
risk of intellectual disability and psychiatric disorder. This is the first study to compare 
the frequency of a broad spectrum of psychiatric disorders in children with 16p11.2 
deletion and duplication. We aimed to evaluate 1) the nature and prevalence of 
psychopathology associated with copy number variation (CNV) in children with 16p11.2 
by comparing deletion and duplication carriers with family controls; 2) whether deletion 
and duplication carriers differ in frequency of psychopathology. 217 deletion carriers, 77 
deletion family controls, 114 duplication carriers and 32 duplication family controls 
participated in the study. Measures included standardized research diagnostic 
instruments. Deletion carriers had a higher frequency of any psychiatric disorder (OR= 
8.9, p<0.001), Attention Deficit Hyperactivity Disorder (ADHD) (OR=4.0, p=0.01) and 
Autism Spectrum Disorder (ASD) (OR=39.9, p=0.01) than controls. Duplication carriers 
had higher frequency of any psychiatric diagnosis (OR=5.3, p=0.01) and ADHD 
(OR=7.0, p=0.02) than controls. The prevalence of ASD in child carriers of deletions 
and duplications was similar (22% vs. 26%). Comparison of the two CNV groups 
indicated higher frequency of ADHD in children with the duplication than deletion 
(OR=2.7, p=0.04) as well as higher frequency of overall psychiatric disorders (OR=2.8, 
p=0.02) and psychotic symptoms (OR=4.7, p=0.02). However, no differences between 
deletion and duplications carriers in the prevalence of ASD were found. Both deletion 
and duplication are associated with increased risk of psychiatric disorder, supporting the 
importance of early recognition, diagnosis and intervention in these groups.  
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Introduction 
Copy number variations (CNVs) in 16p11.2 (deletion and duplication) between break 
points 4 and 5 (BP4-BP5) (600kb, chr16; 29.6-30.2 mb-HG19) occur at a frequency of 
~3 in 10,0001. Around 71% of the 16p11.2 deletions occur de novo while the majority of 
the 16p11.2 duplications (70%) are familial2. This is consistent with the notion that 
16p11.2 deletions have a greater impact on functioning, resulting in reduced fecundity3. 
Both 16p11.2 deletion and duplication have been associated with risk for Autism 
Spectrum Disorder (ASD). Evidence comes from studies of individuals with ASD4-11 with 
a meta-analysis of 3,613 cases reporting a prevalence of 0.50% (95%CI: 0.31%-0.82%) 
for the 16p11.2 deletion and of 0.25% (96%CI: 0.14%-0.56%) for the duplication12. The 
16p11.2 duplication, but not deletion, has been linked to risk of schizophrenia in a meta-
analysis of 16,772 cases reporting a prevalence of 0.35% (95%CI:0.27%-0.45%) in 
cases compared to 0.03% in controls (95%CI:0.02%-0.05%)13. This has been supported 
by comparisons of schizophrenia patients and controls13 and parent-proband trios14. 
The effect of these CNVs on mean IQ is a decrease of approximately two standard 
deviations for the deletion and one standard deviation for the duplication2, 15, 16. Apart 
from ASD, studies of 16p11.2 deletion carriers indicate high frequencies of Attention 
Deficit Hyperactivity Disorder (ADHD) (19%15 to 38%17), anxiety disorders (6%15 to 
25%18), mood disorders (15%18), and Oppositional Defiant Disorder (ODD) and other 
disruptive disorders (13%15 to 39%3). For carriers with the duplication, high rates of 
ADHD (30%3) have been reported. 
Interestingly, these chromosomal rearrangements have been associated with mirrored 
physical phenotypic effects. The 16p11.2 deletion has been associated with risk of 
morbid obesity and large head circumference, while the 16p11.2 duplication has been 
associated with low body mass index (BMI) and small head circumference2, 18, 19. Taking 
into account evidence suggesting links between small head circumference and 
schizophrenia20, 21 and large head circumference with autism22, 23, it has been 
suggested that these mirrored phenotypic effects (overgrowth versus undergrowth 
phenotype) extend to include psychopathology24, although this has not yet been 
formally evaluated. More specifically, it has been suggested that differences in gene 
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dosage associated with a single set of genes within 16p11.2 (deletion) versus three 
copies (duplication) may mediate risk of ASD versus schizophrenia25, 26. The 16p11.2 
CNV has been presented as an example of this theory, such that deletion carriers may 
be at increased risk of ASD in particular, whilst duplication carriers are at risk of ASD 
and schizophrenia2, 18, 26. 
Despite strong evidence that 16p11.2 deletions and duplications are associated with 
increased risk of psychiatric conditions, the majority of studies are based on limited and 
non-systematic assessments (e.g., medical records). Although informative, such 
records are less suited to systematic evaluation of large samples, because of 
differences between medical centers and clinicians in diagnostic methods used and 
clinical documentation. With the exception of schizophrenia and ASD, previous studies 
have been based on relatively small samples, without the availability of control samples 
to allow comparisons. 
Here we report the largest study to date using detailed systematically performed 
psychiatric assessments to determine the nature and prevalence of psychopathology in 
children with deletion or duplication of 16p11.2. We hypothesized that children with 
16p11.2 deletion and duplication have higher frequency of psychiatric disorder than 
family controls. We also hypothesized that deletion carriers would be more severely 
affected than duplication carriers, based on findings that the deletion is more likely to 
arise de novo, whereas the duplication is more frequently inherited. Finally, given the 
evidence that the 16p11.2 CNV is associated with a mirror phenotype of head and body 
size, we hypothesized that the children with 16p11.2 deletion have higher frequency of 
ASD compared to those with 16p11.2 duplication while children with 16p11.2 duplication 
have higher frequency of psychotic symptoms than those with 16p11.2 deletion.  
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Materials/Subjects and Methods 
Sample 
This study combined child samples (age <18 years old) recruited through Medical 
Genetics clinics and collected in Europe (EU) and the US (Table 1). The samples were 
provided from the ECHO study, the 16p11.2 European Consortium, the IMAGINE-ID 
study and the Simons VIP Consortium (Table 2). The sample characteristics of the 
ECHO study, 16p11.2 European Consortium and the Simons VIP Consortium have 
been described elsewhere2, 15. The study methodology and sample assessment of the 
UK ECHO study and IMAGINE-ID project are identical. A subset of these families (i.e., 
from the Simon’s VIP cohort) has been described in prior studies in terms of their IQ, 
ASD and schizophrenia diagnoses2, 27.  
Carrier status for the 16p11.2 deletion or duplication was confirmed for all individuals 
through clinical chromosome microarrays, medical records and/or confirmation in a 
research laboratory. All participants had a CNV in 16p11.2 BP4-BP5 region, excluding 
those in the adjacent region. Family members (siblings) who did not carry the CNV 
participated as family controls (controls) (Table 1). To assess potential recruitment bias 
in children, as a supplementary analysis, we further divided the carriers into a) probands 
(individuals who first came to the attention of medical services) and b) relative carriers 
(i.e., their siblings who were identified and diagnosed following CNV diagnosis of the 
proband) and compared the frequencies of psychiatric diagnoses between these two 
groups. Current analyses included individuals ≥3 years old in order to standardize 
diagnoses, especially for ASD, in very young children15.  
The study was approved by the appropriate local ethics committees and institutional 
review boards. Each participant and his or her caregiver, when appropriate, provided 
informed written consent/assent to participate prior to recruitment.  
 
Psychiatric assessments 
Assessments were performed using research diagnostic instruments as previously 
reported2 under the supervision of experienced and licensed clinicians who gave best 
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estimate clinical and research DSM-IV-TR (Table 2). Only diagnoses that were available 
for all participating sites were examined. Only 2% of children with deletion and 
duplication were diagnosed with any syndromal psychotic disorder vs. 0% of controls. 
Therefore, psychotic symptoms were examined instead.  
IQ scores have already been reported for this sample2. We present the full-scale IQ 
scores and comparisons of psychopathology for subgroups of carriers with and without 
intellectual disability (ID, as defined by IQ ≤70). 
 
Statistical Analysis 
Data analysis was conducted using Stata (version 13)28. Descriptive statistics were 
calculated to assess the frequency of psychiatric disorder. Random effects logit models 
were performed to determine whether group status (e.g., probands vs. controls) 
(independent variable) was associated with increased risk for psychiatric disorder 
(dependent variable: 0=no diagnosis, 1= diagnosis present) while accounting for familial 
clustering (i.e., the family that each individual belongs to). Odds ratios (ORs) and 95% 
confidence intervals (95%CIs) were derived and adjusted for age, sex and cohort status 
(i.e., EU vs. US)2. In cases where the maximum likelihood estimates tended to infinity 
(i.e., rare outcomes/ zero values), Firth’s method29 was used30. To assess recruitment 
bias, we repeated these analyses comparing probands vs. relative carriers. In order to 
reduce the number of statistical comparisons, anxiety disorders were included in the 
analyses as a summary variable (i.e., any anxiety disorder). We tested the associations 
between psychopathology and gender, inheritance status and ID using the phi 
coefficient.  
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Results 
Table 1 shows descriptive statistics of the sample by cohort status (i.e., EU and US).  
1) Deletion carriers versus family controls 
217 carriers and 77 controls were included in the analyses. 48% of the carriers met 
criteria for at least one psychiatric disorder (Table 3, S-Table 1, Figure 1). This 
prevalence was higher than for controls (17%, OR=8.9, p<0.001). The most prevalent 
diagnosis in the carriers was ADHD (29%). This prevalence was higher than in controls 
(13%, OR=4.0, p=0.01). ASD was the second most common diagnosis in carriers 
(22%), which was higher than in controls (0%, OR=39.9, p=0.01). ID was also more 
frequent among carriers (30%) than controls (0%, OR=58.7, p=0.004). No significant 
differences were found in the prevalence of anxiety disorders, ODD/CD, and psychotic 
symptoms in deletion carriers compared to controls. Male children with deletions were 
more likely than females to be diagnosed with any psychiatric disorder, ASD and ID, 
and individuals with inherited deletion were more likely to have ID (S-Table 2).   
2) Duplication carriers versus family controls 
114 carriers and 32 controls were included in the analyses. 63% of the carriers had at 
least one psychiatric disorder (Table 3, S-table 1, Figure 1). This frequency was higher 
than for controls (31%, OR=5.3, p=0.01, Table 3). ADHD was the most common 
diagnosis in the carriers (42%) and was elevated compared to controls (19%, OR=7.0, 
p=0.02). There were no differences in the prevalence of anxiety disorders, ASD, 
ODD/CD and psychotic symptoms between carriers and controls. ID was higher in 
carriers (34%) than controls (3%, OR=56.7, p=0.03). Males were more likely to be 
diagnosed with ODD/CD, and individuals with ID to be diagnosed with ASD (S-table 2).  
3) Deletion versus duplication carriers  
Duplication carriers had higher frequencies of any diagnosis (OR=2.8, p=0.02), ADHD 
(OR=2.7, p=0.04) and psychotic symptoms (OR=4.7, p=0.02) than deletion carriers. No 
other differences were found (Table 3).  
4) Assessment of potential recruitment bias 
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No differences were found between probands and relative carriers with the deletion in 
the prevalence of psychiatric disorders (S-table 3). However, probands with the 
duplication had higher frequencies of any psychiatric disorder than relative carriers 
(OR=3.9, p=0.01).   
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Discussion 
Psychiatric disorders in children with 16p11.2 deletion and duplication 
Our findings indicate that the mental health consequences of the 16p11.2 deletion and 
duplication are broad, similar to findings in other CNVs (e.g., 22q11.2 deletion 
syndrome31, 32). 
ASD frequencies were higher in deletion carriers when compared to controls. In 
addition, almost half of the carriers with either the deletion or duplication were 
diagnosed with at least one psychiatric diagnosis, a frequency much higher than for 
non-carriers. This is similar to previously reported frequencies in medical records-based 
studies of individuals with 16p11.2 deletion33 and duplication3. ADHD was the most 
commonly diagnosed disorder affecting between 30-40% of deletion and duplication 
carriers, similar to the frequencies previously reported3, 15, 17, 18. ID was present in about 
a third of deletion and duplication carriers and was also much more common than 
amongst controls. Frequency of anxiety and ODD/CD disorders and psychotic 
symptoms did not differ between carriers and controls, consistent with previous 
studies15, 18.  
Previous studies in population based samples of CNV carriers have found high 
frequencies of cognitive impairments and psychiatric symptoms24, 34. This indicates that 
these high frequencies are not attributable to recruitment bias but are also 
representative of unselected CNV populations. Indeed, we generally did not find 
evidence of ascertainment bias effects on phenotypic assessment, as the frequencies of 
psychiatric diagnoses did not differ between probands and relative carriers. The only 
exception was our finding of higher frequencies of any psychiatric diagnoses in child 
duplication compared to relative carriers. 
Although we found evidence for differences in the prevalence of psychotic symptoms, 
we did not find evidence for differences in the prevalence of ASD between 16p11.2 
deletion and duplication carriers, for which we had more power. Thus, our findings do 
not provide support of a mirror phenotype for psychiatric disorder. More generally, both 
deletion and duplication showed significant and overlapping psychopathology and any 
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differences were of degree rather than suggesting contrasting mirror effects at the level 
of psychopathology.  
Interestingly, we found associations between sex and any psychiatric disorder, ASD and 
ID in children with 16p11.2 deletion and ODD/CD in children with 16p11.2 duplication, 
indicating increased risk for males. No other associations were found with ADHD or 
psychotic symptoms which agrees with a previous study that examined questionnaire 
responses18 as well as with findings related to another CNV on chromosome 22, 
resulting in 22q11.2 deletion syndrome32. These findings point to possible negation of 
sex-related burden to some psychiatric disorders by these CNVs35. Apart from an 
increased risk of ASD in children with 16p11.2 duplication, psychiatric disorders did not 
occur more frequently in participants with ID in children with 16p11.2 deletion or 
duplication. Although this could reflect insufficient power, it could also indicate that 
these CNVs have pleiotropic effects on IQ and psychopathology36. Finally, there was an 
association between inherited status and higher risk of ID indicating that potential 
parental genetic and environmental effects might be negatively implicated on child 
intelligence. There were no other associations with inheritance status and psychiatric 
diagnoses, similar to a previous study15. 
Strengths and limitations 
This is the largest study to date to perform detailed phenotypic assessments on children 
with 16p11.2 deletion and duplication and compare the frequency of psychopathology 
with familial controls as well as between deletion and duplication carriers.  
Our findings may be influenced by ascertainment bias. First, although we did not recruit 
individuals from psychiatric services, ascertainment was based on a phenotype 
significant enough to trigger clinical genetic testing (e.g., developmental delay). Second, 
although for many phenotypes we did not find evidence for recruitment bias in our 
analyses, we did find higher frequencies of any psychiatric diagnoses in child 
duplication probands compared to child relative carriers. We have previously explained 
our ascertainment strategies and limitations15, 32. It is noteworthy that there were 
relatively high frequencies of psychopathology in familial controls. 17% and 31% of non-
carrier child relatives of individuals with deletion and duplication, respectively, met 
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criteria for at least one psychiatric diagnosis. The frequencies of ADHD (13% for 
deletion and 19% for duplication) and ASD (7% for duplication) were higher than we 
would expect from a population-based sample (5-7% and 1%, respectively). Potential 
explanations could be increased background environmental risk (e.g., the effect of 
family psychopathology), or perhaps the presence of polygenic or other additional 
genetic background effects that could also be a result of assortative mating. 
Irrespectively, our findings indicate that carriers of deletion or duplication of CNV at 
16p11.2 who come to the attention of Medical Genetics services are at high risk of 
psychiatric disorder, and this is of importance for treating clinicians as well as the 
families themselves. If anything, our estimates represent an underestimate, given that 
the risks are elevated in our comparison sample of non-carrying familial controls. 
Finally, the assessments at all sites were made by experienced clinicians and highly 
trained and clinically supervised psychologists. However, there were differences in the 
frequencies of psychiatric diagnoses and ID and although we adjusted for cohort status, 
we cannot exclude that potentially different diagnostic practices between the sites and 
countries in this study might have played a role in our findings. Further research is 
needed to examine psychopathology associated with these CNVs in population-based 
samples as well as to understand their longitudinal course. 
Clinical implications and future directions 
This study clearly indicates that the phenotypic effects of the 16p11.2 deletion and 
duplication extend to include non-ASD psychopathology. The high frequency of 
psychiatric disorders, especially ADHD, in childhood indicate the need for recognition, 
diagnosis and treatment early in development. Longitudinal studies are needed to 
examine the natural history of these disorders and whether specific types of treatment 
(e.g., stimulant medication for ADHD) are beneficial37. Not all children met criteria for a 
psychiatric disorder, supporting previous literature indicating that there is a spectrum of 
manifestations of the 16p11.2 deletions and duplications7, similar to other CNVs (e.g., 
22q11.2DS32).  
Future studies could examine the extent to which assortative mating plays a role in 
psychiatric risk in children from families where a CNV is inherited compared to where it 
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occurs de novo. Further exploration of the extent to which background genetic as well 
as environmental risk factors contribute to risk of psychiatric disorder in carriers with a 
de novo versus an inherited CNV is also important.  
Conclusions 
We examined the frequency of psychopathology in children with 16p11.2 deletion and 
duplication. Our findings indicate a high frequency of psychopathology compared to 
familial controls and suggest the importance of recognition, diagnosis and intervention 
in early development. The frequency of psychotic symptoms and ASD are similar in 
deletion and duplication carriers, indicating that mirrored physical effects of deletion and 
duplication do not extend to psychopathology.  
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 Table 1. Description of 16p11.2 cohort, carrier groups and controls 
 
Cohort by carrier group Sample size Male (%) Age, mean(SD) De Novo(%) Inherited 
16p11.2 deletion      
European      
Carriers 101 65(64%) 9.5(3.1) 45(56%) 36(44%) 
Controls 22 16(73%) 9.8(3.1   
United States      
Carriers 116 61(53%) 8.5(3.3) 67(74%) 23(26%) 
Controls 55 20(36%) 9.8(4.0)   
16p11.2 duplication      
European      
Carriers 46 30(65%) 9.0(3.3) 9(24%) 29(76%) 
Controls 7 5(71%) 10.6(5.7)   
United States      
Carriers 68 35(52%) 8.1(3.7) 9(16%) 46(84%) 
Controls 25 13(52%) 8.1(3.9)   
Notes:  Counts of De Novo and Inherited do not add up to 100% because a number of carriers 
were of unknown status. Percentages are estimated not taking into account individuals with 
unknown status. 
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Table 2. Measures used in the European and United States cohorts 
Cohort Studies included Measures  
European(EU) ECHO  CAPA & ADI-R 
 IMAGINE-ID CAPA & ADI-R 
 16p11.2 European 
Consortium 
Clinical interviews & the Conners CBRS for 
children, ADI-R and ADOS  
United 
States(US) 
Simons VIP Consortium DISC and clinical observations for all subjects 
in combinations with IQ testing and supporting 
measures (SCL-90, BAPQ, SRS), ADI-R and 
ADOS 
Abbreviations: ECHO = the Cardiff University ExperienCes of people witH cOpy number 
variants (ECHO) study (see http://medicine.cf.ac.uk/psychological-medicine-neuroscience/areas-
research/copy-number-variant-research/research-projects/), IMAGINE-ID = intellectual disability 
and mental health: assessing genomic impact on neurodevelopment (see: http://www.imagine-
id.org/). Simons VIP Consortium = the Simons Variation in Individuals Project (VIP) Consortium 
(see https://www.simonsvipconnect.org/). CAPA = Child and Adolescent Psychiatric Assessment 
(CAPA); Conners CBRS = Conners Comprehensive Behavior Rating Scales 38; DISC = 
Diagnostic Interview Schedule for Children 39; ADI-R = the Autism Diagnostic Interview – Revised 
40; ADOS = the Autism Diagnostic Observation Schedule 40; SCL-90 = Symptom Checklist – 90 
41; BAPQ = Broad Autism Phenotype Questionnaire (Hurley, Losh et al. 2007); SRS = Social 
Responsiveness Scale 42. 
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Table 3. Psychiatric diagnoses, psychotic symptoms and intellectual disability in 
children by 16p11.2 status 
 
CHILDREN Deletion 
 Carriers (N=217) Controls (N= 77) Odds ratio  
 N(%) N(%)  (95%CI) p 
Any diagnosis 105(48) 13(17) 8.9(2.9-27.3) p<0.001 
Any anxiety disorder 20(9) 2(3) 3.0(0.7-13.4) 0.16 
ADHD 63(29) 10(13) 4.0(1.3-11.9) 0.01 
ASD 41(22) 0(0) 39.9(2.4-660.5) 0.01 
Psychotic 
symptoms 
5(4) 2(4) 0.6(0.1-2.7) 0.46 
ODD/CD 15(7) 0(0) 9.3(0.5-159.2) 0.12 
ID* 61(30) 0(0) 58.7(3.5-973.1) 0.004 
 Duplication 
 Carriers (Ν=114) Controls (N=32) Odds ratio  
 N(%) N(%)  (95%CI) p 
Any diagnosis 72(63) 10(31) 5.3(1.6-17.1) 0.01 
Any anxiety disorder 14(12) 1(3) 2.6(0.3-23.6) 0.38 
ADHD 48(42) 6(19) 7.0(1.4-35.9) 0.02 
ASD 26(26) 3(7) 4.5(0.7-27.3) 0.10 
Psychotic 
symptoms 
7(11) 0(0) 2.2(0.10-49.2) 0.61 
ODD/CD 14(12) 1(3) 5.1(0.6-46.0) 0.14 
ID* 36(34) 1(3) 56.7(1.5-2193.2) 0.03 
 Duplication vs. deletion 
 Odds ratio (95%CI) p 
Any diagnosis 2.8(1.2-6.7) 0.02 
Any anxiety disorder 2.0(0.9-4.5) 0.09 
ADHD 2.7(1.0-7.1) 0.04 
ASD 1.4(0.6-3.0) 0.44 
Psychotic 
symptoms 
4.7(1.3-17.8) 0.02 
ODD/CD 2.1(1.0-4.7) 0.06 
ID* 1.8(0.7-4.5) 0.19 
Notes: Not all individuals had complete data on all diagnoses. Bold indicates p<0.05. ID was 
not included in the overall rates of ‘any diagnosis’. The percentages represent the proportion of 
individuals with available diagnoses. 
Abbreviations: ADHD=Attention Deficit Hyperactivity Disorder; ASD=Autism Spectrum 
Disorder; ODD/CD=Oppositional Defiant Disorder/Conduct Disorder. * defined by IQ<=70  
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S-Table 1. Psychiatric diagnoses, psychotic symptoms and intellectual disability in children by 16p11.2 status, cohort and carrier group 
CHILDREN 16p11.2 deletion 16p11.2 duplication 
 Europe United States Europe United States 
 Carriers Carrier 
relatives 
Controls Carriers Carrier 
relatives 
Controls Carriers Carrier 
relatives 
Controls Carriers Carrier 
relatives 
Controls 
N 87 14 22 106 10 55 39 7 7 50 18 25 
 Mean(SD) Mean(SD) Mean(SD) Mean(SD) Mean(SD) Mean(SD) Mean(SD) Mean(SD) Mean(SD) Mean(SD) Mean(SD) Mean(SD) 
IQ 73.8(14.1) 69.6(14.1) 99.2(12.6) 84.6(15.8) 81.3(16.4) 106.8(9.8) 67.5(21.9) 79(20.6) 103(18.2) 77.2(21.4) 85.9(17.8) 100.7(19.7) 
 N(%) N(%) N(%) N(%) N(%) N(%) N(%) N(%) N(%) N(%) %(N) N(%) 
Intellectual 
disability* 
31(41) 8(57) 0(0) 20(19) 2(22) 0(0) 15(44) 2(33) 0(0) 16(33) 3(17) 1(4) 
Any diagnosis 41(47) 4(29) 3(15) 57(54) 3(30) 10(18) 29(74) 4(57) 2(29) 33(66) 6(33) 8(32) 
Any anxiety 
disorder 
13(15) 2(14) 0(0) 5(5) 0(0) 2(4) 7(18) 3(43) 0(0) 3(6) 1(6) 1(4) 
Specific 
phobia 
3(3) 0(0) 0(0) 0(0) 0(0) 0(0) 4(10) 1(14) 0(0) 1(2) 0(0) 0(0) 
Social Phobia 9(10) 0(0) 0(0) 1(1) 0(0) 0(0) 1(3) 2(29) 0(0) 0(0) 0(0) 1(4) 
SAD 4(5) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 1(14) 0(0) 0(0) 0(0) 0(0) 
Agoraphobia 4(5) 1(7) 0(0) 0(0) 0(0) 0(0) 2(5) 1(14) 0(0) 0(0) 0(0) 0(0) 
OCD 2(2) 1(7) 0(0) 0(0) 0(0) 0(0) 0(0) 1(14) 0(0) 2(4) 0(0) 0(0) 
GAD 2(2) 1(7) 0(0) 4(4) 0(0) 2(4) 6(15) 2(29) 0(0) 0(0) 1(6) 0(0) 
MDD 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 
Dysthymic 
disorder 
1(1) 0(0) 0(0) 0(0) 0(0) 1(2) 1(3) 0(0) 0(0) 1(2) 0(0) 0(0) 
ADHD 27(31) 3(21) 3(15) 32(30) 1(10) 7(13) 15(38) 4(57) 2(29) 24(48) 5(28) 4(16) 
ASD 12(19) 0(0) 0(0) 27(25) 2(20) 0(0) 12(43) 0(0) 0(0) 12(24) 2(11) 3(12) 
ODD/CD 7(8) 2(14) 0(0) 6(6) 0(0) 0(0) 4(10) 3(43) 0(0) 7(14) 0(0) 1(4) 
Psychotic 
symptoms 
5(10) 0(0) 2(13) 0(0) 0(0) 0(0) 6(40) 0(0) 0(0) 1(3) 0(0) 0(0) 
Any psychosis 0(0) 0(0) 0(0) 4(4) 0(0) 0(0) 1(3) 0(0) 0(0) 0(0) 1(6) 0(0) 
Schizophrenia 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 1(6) 0(0) 
Substance/alc
ohol abuse 
0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 1(3) 0(0) 0(0) 0(0) 0(0) 0(0) 
Abbreviations: SAD=Separation Anxiety Disorder; OCD=Obsessive Compulsive Disorder; GAD=Generalized Anxiety Disorder; MDD=Major Depressive Disorder; ADHD=Attention Deficit 
Hyperactivity Disorder; ASD=Autism Spectrum Disorder; ODD/CD=Oppositional Defiant Disorder/Conduct Disorder. * defined by IQ<=70 ** no ASD diagnosis available 
S-Table 2. Relationship between sex, inheritance and intellectual disability with psychopathology in children with 16p11.2 deletion and duplication 
 
CHILDREN    
16p11.2 deletion    
Diagnosis Males/Females Inheritance 
(de novo/inherited) 
Intellectual disability* 
(No/Yes) 
Intellectual disability -0.15 (p=0.03) 0.19 (p=0.01)  
Any diagnosis -0.13(p=0.05) -0.13 0.08 
Any anxiety disorder -0.05 0.04 0.07 
ADHD -0.05 -0.09 0.02 
ODD/CD -0.05 -0.11 0.12 
Psychotic symptoms -0.09 0.08 -0.02 
ASD -0.16(p=0.03) -0.16 0.05 
    
16p11.2 duplication    
Diagnosis Males/Females Inheritance 
(inherited/de novo) 
Intellectual disability* 
Intellectual disability 0.05 -0.04  
Any diagnosis -0.15 -0.18 0.10 
Any anxiety disorder -0.00 0.07 -0.20(p=0.03) 
ADHD -0.06 -0.10 -0.18 
ODD/CD -0.22(p=0.02) 0.19 -0.13 
Psychotic symptoms 0.18 0.10 -0.04 
ASD -0.10 -0.11 0.45(p<0.001) 
In bold significant associations with p<0.05. Negative associations signify that males/inherited/no 
intellectual disability are at greater risk.  
Abbreviations: ADHD=Attention Deficit Hyperactivity Disorder, ODD/CD=Oppositional Defiant 
Disorder/Conduct Disorder, ASD=Autism Spectrum Disorder, MDD=Major Depressive Disorder 
* defined by IQ<=70 
S-Table 3. Assessing recruitment bias.  
 
 
CHILDREN Any diagnoses Any anxiety ADHD ODD/CD Psychotic symptoms ASD 
Comparisons OR(95%CI) p OR(95%CI) p OR(95%CI) p OR(95%CI) p OR(95%CI) p OR(95%CI) p 
Deletion             
Probands vs. 
relative carriers 
2.7(0.7-10.9) 0.17 1.1(0.2-5.7) 0.87 2.9(0.4-20.3) 0.29 0.8(0.2-3.7) 0.76 1.1(0.0-25.6) 0.97 2.7(0.4-16.2) 0.37 
Duplication             
Probands vs. 
relative carriers 
3.9(1.3-11.5) 0.01 0.4(0.1-1.8) 0.21 1.5(0.4-5.2) 0.50 0.7(0.2-3.2) 0.66 7.9(0.3-196.1) 0.21 4.0(0.8-18.7) 0.08 
ORs adjusted for cohort, age and sex; Reference group is in italics; ASD=Autism Spectrum Disorder, ADHD=Attention Deficit Hyperactivity Disorder, ODD/CD=Oppositional Defiant 
Disorder/Conduct Disorder, ASD=Autism Spectrum Disorder 
 
Abbreviations: ADHD=Attention Deficit Hyperactivity Disorder, ASD=Autism Spectrum Disorder, ID=Intellectual 
Disability, ODD/CD=Oppositional Defiant Disorder/Conduct Disorder, PS=Psychotic symptoms 
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Figure	1.	Frequency	of	psychiatric	diagnoses,	psychotic	symptoms	and	intellectual	disability in	children	with	16p11.2	deletion	and	
duplication
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